Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Journal of Autoimmunity|November 29, 2011
Gender-based blood transcriptomes and interactomes in multiple sclerosis: involvement of SP1 dependent gene transcriptionRamesh Menon, Marco Di Dario, Chiara Cordiglieri, et al.
Neuro-Oncology|November 20, 2012
Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologiesAnna Luisa Di Stefano, Victor Enciso-Mora, Yannick Marie, et al.
Neuro-Oncology Advances|August 16, 2021
Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemicFernando Lozano-Sanchez, Renata Ursu, Anna Luisa Di-Stefano, et al.
The Journal of Biological Chemistry|October 26, 2006
Human TFDP3, a novel DP protein, inhibits DNA binding and transactivation by E2FHuan Qiao, Luisa Di Stefano, Chan Tian, et al.
Cells|March 27, 2024
Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro SamplingMariangela Morelli, Francesca Lessi, Sara Franceschi, et al.
Acta Neuropathologica|February 21, 2018
Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk lociKarim Labreche, Ben Kinnersley, Giulia Berzero, et al.
The Oncologist|July 28, 2025
Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinibFederico Villanacci, Diego Prost, Francesco Pieri, et al.
Biomed Research International|May 8, 2014
An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomasJulien Laffaire, Anna Luisa Di Stefano, Olivier Chinot, et al.
Neurology|May 6, 2018
FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomasAlberto Picca, Giulia Berzero, Franck Bielle, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2024
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomasAlberto Picca, Mehdi Touat, Lisa Belin, et al.
Pageof 9